The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
|Videos|May 19, 2022
Dr. Harper on risk factors for increased stent-associated symptoms after ureteroscopy for stones
Author(s)Urology Times staff
“A ureteral stent can be bothersome, but it’s quite variable. Some people don’t even feel the stent and some people have severe symptoms,” says Johnathan Harper, MD.
Advertisement
Lead study author Johnathan Harper, MD discusses the background and results of the study, “Risk Factors For Increased Stent-Associated Symptoms Following Ureteroscopy For Urinary Stones: Results From The Urinary Stone Disease Research Network (USDRN) Stents Study,” which he presented at the 2022 AUA Annual Meeting (abstract LBA02-08).
Harper is a professor of Urology and chief of Endourology and Minimally Invasive Surgery at the University of Washington
Advertisement
Related to this article
The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.
A decision is expected by the fourth quarter of 2026.
Marian Cuello joins to discuss sexual wellness and the importance of normalizing conversations about sexual health for all individuals.
Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.
Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
The clearance expands access to the LigaSure vessel-sealing technology within robotic surgical workflows.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants RMAT designation to EG110A for neurogenic detrusor overactivity
2
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
3
CHMP recommends perioperative enfortumab vedotin plus pembrolizumab for MIBC
4
PSMA-PET in clinical practice: Juan Gómez Rivas, MD, on barriers to access
5